207 related articles for article (PubMed ID: 30410015)
41. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma.
Ma X; Zhu H; Guo H; Han A; Wang H; Jing W; Zhang Y; Kong L; Yu J
Oncotarget; 2016 Dec; 7(49):81906-81917. PubMed ID: 27626317
[TBL] [Abstract][Full Text] [Related]
42. [Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].
Chen L; Fu M; Zhou J; Yao Y; Zhou J
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):312-318. PubMed ID: 31109441
[TBL] [Abstract][Full Text] [Related]
43. Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma.
Hayasaka K; Shiono S; Matsumura Y; Yanagawa N; Suzuki H; Abe J; Sagawa M; Sakurada A; Katahira M; Takahashi S; Endoh M; Okada Y
Ann Thorac Surg; 2018 Jun; 105(6):1648-1654. PubMed ID: 29486179
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer.
Guo D; Zhang J; Jing W; Liu J; Zhu H; Fu L; Li M; Kong L; Yue J; Yu J
Future Oncol; 2018 Oct; 14(25):2643-2650. PubMed ID: 29747545
[TBL] [Abstract][Full Text] [Related]
45. Systemic immune-inflammation index for predicting prognosis of colorectal cancer.
Chen JH; Zhai ET; Yuan YJ; Wu KM; Xu JB; Peng JJ; Chen CQ; He YL; Cai SR
World J Gastroenterol; 2017 Sep; 23(34):6261-6272. PubMed ID: 28974892
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet.
Xiong Y; Zhao N; Zheng Y; Wang J; Wei F; Ren X
Tumour Biol; 2017 Jun; 39(6):1010428317701639. PubMed ID: 28618954
[TBL] [Abstract][Full Text] [Related]
47. The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.
Mizutani K; Guo X; Shioya A; Zhang J; Zheng J; Kurose N; Ishibashi H; Motono N; Uramoto H; Yamada S
Int J Med Sci; 2019; 16(9):1199-1206. PubMed ID: 31588184
[No Abstract] [Full Text] [Related]
48. Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis.
Rau KM; Chen HK; Shiu LY; Chao TL; Lo YP; Wang CC; Lin MC; Huang CC
Int J Mol Sci; 2016 Apr; 17(4):524. PubMed ID: 27070580
[TBL] [Abstract][Full Text] [Related]
49. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS; Patel PR; Curran WJ; Shu HG; Sica GL; Higgins KA
Cancer; 2018 Sep; 124(17):3586-3595. PubMed ID: 30120912
[TBL] [Abstract][Full Text] [Related]
50. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Jain A; Lim C; Gan EM; Ng DZ; Ng QS; Ang MK; Takano A; Chan KS; Tan WM; Kanesvaran R; Toh CK; Loo CM; Hsu AA; Devanand A; Lim CH; Koong HN; Koh T; Fong KW; Yap SP; Kim SW; Chowbay B; Oon L; Lim KH; Lim WT; Tan EH; Tan DS
PLoS One; 2015; 10(5):e0123587. PubMed ID: 25955322
[TBL] [Abstract][Full Text] [Related]
51. Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer.
Gao Y; Zhang H; Li Y; Wang D; Ma Y; Chen Q
Clin Chim Acta; 2018 Sep; 484():272-277. PubMed ID: 29860033
[TBL] [Abstract][Full Text] [Related]
52. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
[TBL] [Abstract][Full Text] [Related]
53. Prognostic nutritional index and systemic immune-inflammation index are prognostic biomarkers for non-small-cell lung cancer brain metastases.
Li W; Qu Y; Wen F; Yu R; He X; Jia H; Liu H; Yu H
Biomark Med; 2021 Sep; 15(13):1071-1084. PubMed ID: 34397267
[No Abstract] [Full Text] [Related]
54. Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function.
Zhou J; Ben S
Thorac Cancer; 2018 Feb; 9(2):228-233. PubMed ID: 29222872
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of prognostic nutritional index and systemic immune-inflammation index in patients with osteosarcoma.
Huang X; Hu H; Zhang W; Shao Z
J Cell Physiol; 2019 Aug; 234(10):18408-18414. PubMed ID: 30891768
[TBL] [Abstract][Full Text] [Related]
56. Systemic Immune-inflammation Index is the Best Prognostic Factor in Patients with Advanced Stage Adenocarcinoma of the Lung Treated with Pemetrexed.
Bilgetekin I; Basal FB
J Coll Physicians Surg Pak; 2020 Sep; 30(9):933-939. PubMed ID: 33036677
[TBL] [Abstract][Full Text] [Related]
57. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.
Yang WC; Xiao F; Shih JY; Ho CC; Chen YF; Tseng HM; Chen KY; Liao WY; Yu CJ; Yang JC; Kuo SH; Cheng JC; Yang PC; Hsu FM
Radiother Oncol; 2018 Feb; 126(2):368-374. PubMed ID: 29111173
[TBL] [Abstract][Full Text] [Related]
58. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
[TBL] [Abstract][Full Text] [Related]
59. Prognostic impact of preoperative monocyte counts in patients with resected lung adenocarcinoma.
Kumagai S; Marumo S; Shoji T; Sakuramoto M; Hirai T; Nishimura T; Arima N; Fukui M; Huang CL
Lung Cancer; 2014 Sep; 85(3):457-64. PubMed ID: 25043641
[TBL] [Abstract][Full Text] [Related]
60. Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma--The Results of Three Year Retrospective Analysis.
Bittner N; Balikó Z; Sárosi V; László T; Tóth E; Kásler M; Géczi L
Pathol Oncol Res; 2015 Sep; 21(4):1217-21. PubMed ID: 26055897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
